Respirology
Expert Brief 3: Dual vs. Triple Therapy in Patients with a History of ≥ 1 Exacerbation in the Past Year
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common […]
DURATION
15 min
PROFESSION
Physician
# OF CREDITS
0.3
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-09-30
COPD is one of the most common conditions seen in primary care. With the many options that can be considered for these patients, it is important for primary care clinicians be aware of the current evidence to guide treatment. This series will review current evidence, compare it to current guidelines and apply it to common cases seen in clinical practice.
This program has received an unrestricted educational grant or in-kind support from GSK.
Faculty
John Axler, MD, LMCC, CCFP, FCFP
Andre Belanger, MD, CFPC
Jeff Habert, MD, CCFP, FCFP
Sol Stern, Bsc, MD, MCFP
Learning objectives
Upon completion of this continuing education program, participants will be better able to:
- Contrast the current evidence supporting the use of dual bronchodilation (LAMA/LABA) versus triple therapy (ICS/LAMA/LABA) in a patient with a history of one acute exacerbation of (AECOPD) in the past year
- Discuss the risk-benefit considerations in using LAMA/LABA versus ICS/LAMA/LABA
Accreditation
This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.3 Mainpro+ credits.
This program is developed in collaboration with ICEBM.